|
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITINGPhase 3Sponsored by M.D. Anderson Cancer Center
Actively Recruiting
PhasePhase 3
SponsorM.D. Anderson Cancer Center
Started2022-10-14
Est. completion2027-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05053867
Summary
This is a drug study that will examine if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age \> 18 years old 2. Have a diagnosed hematological malignancy 3. Are actively receiving mechanical ventilation 4. Have evidence of pulmonary hemorrhage as defined by either 1. Persistently bloody secretions upon endotracheal tube suctioning, or 2. Evidence of diffuse alveolar hemorrhage by bronchoscopic examination 5. Signed informed consent by patient or if the subject lacks decision-making capacity, the subject's legally authorized representative 2.3.2 Exclusion Criteria Patients excluded from participation in the study if any of the following criteria are met: 1. Presence of a Do Not Resuscitate (DNR), no escalation of care or comfort care order at the time of screening 2. Expected survival \< 48 hours 3. Evidence of nasal or oral spillage likely to be the cause of bloody secretions 4. Patients requiring 100% FIO2 5. Known hypersensitivity to tranexamic acid 6. Treatment with inhaled tranexamic acid prior to screening 7. Acquired defective color vision 8. Subarachnoid hemorrhage 9. Deep Venous or arterial thrombus diagnosed within the previous 3 months 10. Seizure disorder on active anti-epileptic therapies 11. Hypersensitivity to tranexamic acid or any of the ingredients 12. Pregnant women will not be eligible and have a negative pregnancy test prior to entering study 13. Patient receiving concurrent anti-fibrinolytic therapy 14. Confirmed active COVID-19 infection
Conditions3
CancerLung CancerPulmonary Hemorrhage
Interventions1
Locations1 site
Find trials near these locations
Related trials
- Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial — RenJi Hospital
- Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia — University of Manitoba
- Perioperative Treatment With Tranexamic Acid in Melanoma — University of Aarhus
- Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) — Ottawa Hospital Research Institute
- Tranexamic Acid During Colonic Endoscopic Resection Procedures — Assaf-Harofeh Medical Center
- Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients — Second Affiliated Hospital, School of Medicine, Zhejiang University
- The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients — Stanford University
- Role of TXA in Patients Undergoing Breast Free Flap Reconstruction — University of Virginia
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorM.D. Anderson Cancer Center
Started2022-10-14
Est. completion2027-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT05053867